Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    

 SummaryNewsCalendarCompanyFinancials 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against... 
More about the company
Latest news on CEL-SCI CORPORATION
04/20 CEL SCI : Scientist Presents at the World Vaccine Congress
04/12 CEL SCI : Scientist Presents at the World Vaccine Congress
03/16 CEL SCI : Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer ..
03/10 CEL-SCI CORPORATION (NYSEMKT : CVM) Files An 8-K Entry into a Material Definitiv..
03/09 CEL SCI : Announces $1.5 Million Registered Direct Offering
03/08 CEL-SCI CORPORATION : Blog Coverage CEL-SCI Provides Update on Late-stage Multik..
03/07 CEL SCI CORP : Other Events, Financial Statements and Exhibits (form 8-K)
03/06 CEL SCI : NEW STORY CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Hea..
03/06 CEL SCI : Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer ..
03/02 CEL SCI : Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vac..
More news
Sector news : Bio Therapeutic Drugs
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Bio Therapeutic Drugs
Advertisement
Managers
NameTitle
Geert R. Kersten CEO, CFO, Treasurer, Director & CAO
Patricia B. Prichep Secretary & Senior Vice President-Operations
Eyal Talor Chief Scientific Officer
Alexander G. Esterhazy Independent Director
Peter R. Young Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CEL-SCI CORPORATION20
AMGEN, INC.9.71%118 044
CELGENE CORPORATION5.62%95 114
GILEAD SCIENCES, INC.-7.93%86 186
REGENERON PHARMACEUTIC..0.83%39 263
ACTELION LTD26.98%30 294
More Results